The efficacy of structure-modified drugs in the treatment of patient with osteoarthritis and hyperuricemia
I and II groups. After 6 moths of treatment the statistically significant decrease of IL-1, NO, and statistically significant increase of IGF-1 were observed. Patients of III groups had decrease of IL-1 (p < 0.05) more substantial than patients of I and II groups. The tendency towards increase of uricemia in I group, its statistically significant increase in II group and decrease in III group were revealed. Conclusion: the usage of medication with chondroitin-4,6-sulfate to treat the patients with OA and concomitant hyperuricemia is pathogeneticaly grounded and clinically promising, however, its influence on the uricemia level should be taken into consideration and differential approach to the treatment of patients with OA and concomitant hyperuricemia should be planned prescribing structure modifying agents combined with medication lowering hyperuricemia.
Full Text:PDF (Українська)
EULAR evidence based recommendations for the manage¬ment of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) / W. Zhang, M. Doherty, B. F. Leeb [et al.] // Ann. Rheum. Dis. — 2007. — Vol. 66. — P. 377–388, doi:10.1136/ard.2006.062091.
EULAR evidence based recommendations for the management of hip osteoarthritis: report of task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutic (ESCISIT) / W. Zhang, M. Doherty, N. Arden [et al.] //Ann. Rheum. Dis. — 2005. — Vol. 64 (5). — P. 669–681, doi:10.1136/ard.2004.028886.
EULAR Recommendation 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) / K. M. Jor¬dan, N. K. Arden, M. Doherty [et al.] // Ann. Rheum. Dis. — 2003. — Vol. 62 (12). — P. 1145–1155, doi:10.1136/ard.2003.011742.
An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Eco¬nomic Aspects of Osteoporosis and Osteoarthritis (ESCEO) / O. Bruyere, C. Cooper, J. P. Pelletier [et al.] // Semin. Arthritis Rheum. — 2014. — Vol. 44 (3). — Р. 253–263, doi: http://dx.doi.org/10.1016/j.semarthrit.2014.05.014.
OARSI recommendations for the management of hip and knee osteoarthritis : part III: Changes in evidence following systematic cumulative update of research published through January 2009 / W. Zhang, G. Nuki, R. W. Moskowitz [et al.] // Osteoarthritis Cartilage. — 2010. — Vol. 18 (4). — P. 476–499, doi: 10.1016/j.joca.2010.01.013.
Antioxidant, anti-inflammatory and neuroprotective actions of chondroitin sulfate and proteoglycans / J. Egea, A. G. Garsia, J. Verges [et al.] // Osteoarthritis and Cartilage. — 2010. — Vol. 18, Suppl. 1. — P. 24–27, doi: 10.1016/j.joca.2010.01.016.
Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis / G. Herrero-Beaumont, M. E. Marcus, O. Sanchez-Pernaute [et al.] // Br. J. Pharmacol. — 2008. — Vol. 154 (4). — P. 843–851, doi: 10.1038/bjp.2008.113.
Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee / R. Altman, E. Asch, D. Bloch [et al.] // Arthritis Rheum. — 1986. — Vol. 29 (8). — P. 1039–1049.
2011 recommendations for the diagnosis and management of gout and hyperuricemia / M. Hamburger, H. S. Baraf, T. C. Ad¬amson, [et al.] // Phys. Sportsmed. — 2011. — Vol. 39 (4). — P. 98–123, doi: 10.3810/psm.2011.11.1946.
Kellgren J. H., Lawrence J. S Radiological assessment of osteoarthrosis / J. H. Kellgren, J. S. Lawrence // Annals of The Rheumatic Diseases. — 1957. — Vol. 16. — Р. 494–450.
Copyright (c) 2015 Neonila Shuba, Anna Krylova
This work is licensed under a Creative Commons Attribution 4.0 International License.